logo
Plus   Neg
Share
Email

Genentech: Gazyva Meets Endpoints In Phase II Lupus Nephritis Trial

Genentech, a member of the Roche Group (ROG.SW,RO.SW), said a Phase II clinical trial investigating Gazyva for adults with proliferative lupus nephritis met its primary endpoint. Gazyva, in combination with standard of care, demonstrated enhanced efficacy compared to placebo plus standard of care alone in achieving complete renal response at one year. Gazyva also met key secondary endpoints in the study.

Gazyva is an engineered monoclonal antibody designed to attach to CD20, a protein found only on certain types of B-cells. In the U.S., Gazyva is part of an association between Genentech and Biogen.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. is taking necessary precautions including Covid-19 testing for those employees returning to work at its headquarters in Silicon Valley, Bloomberg reported citing people familiar with the process. The company, which opened its main Apple Park office in May bringing back some hardware and software engineers, plans the gradual reopening of the building keeping the coronavirus safeguards. A U.S. appeals court has blocked the sales of Bayer AG's dicamba-based Xtendimax in the United States. The three-judge panel in the U.S. Court of Appeals for the Ninth Circuit ruled that the US Environmental Protection Agency (EPA) overstated the protections and substantially understated or ignored the risks related to the use of dicamba-based herbicides. Tesla Chief Executive Officer Elon Musk has called for a breakup of Amazon after the online retail giant refused to publish an upcoming book about COVID-19. Writer Alex Berenson said on Twitter that Amazon refused to publish his booklet about the coronavirus as it did not comply with the company's guidelines. Berenson is a former New York Times reporter.
Follow RTT